While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of…
At the mid-year point of 2021, what are the nation’s leading newsletter advisors’ favorite investment ideas for the remainder of the year? Today’s article reviews some of their top-performing picks from the beginning of the year and asks them for their mid-year updates. For ideas spanning biotech, cryptocurrency, electric vehicles, space exploration and more, CLICK HERE.
The author of today’s article’s favorite healthcare stock right now is a tech stock for the healthcare industry whose software is helping revolutionize the drug discovery process. More specifically, its solution “helps big pharma find the right molecule for the right target, and it helps them do it a lot quicker than normal human research” – and it’s being used…
While biotech companies are some of the largest disruptors in the broader healthcare sector, broad healthcare indexes tend to lack concentrated biotech exposure. As such, for investors choosing to follow an index strategy, the author of today’s article highlights two indexes that offer exposure to biotech stocks that have one or more drugs in Phase II and Phase III U.S.…
The price of Dogecoin – the current star of the cryptocurrency world – has fallen significantly from its recent highs. This has the author of today’s article advising that, “with the crypto bubble on shaky ground, aggressive investors might be wise to consider alternative growth vehicles soon” – and he highlights two biotech penny stocks to consider as those alternative…
The clinical-stage biotech featured in today’s article, focused on developing treatments for fibrosis, cancer and other related diseases, has gained 18.7% over the past month. In order to determine whether it can continue its ascension and become a winner in the biotech industry, the author takes a look at the factors that could influence its performance in the coming months.…
Companies involved in stem cell therapies, cannabis overdose treatments, COVID-19 vaccinations and the treatment of lupus make up the four new biotech stocks to watch highlighted in today’s article, which also highlights a number of new stocks to watch in the mining sector (including those involved in “battery metals” such as graphite and lithium). For all of these new stocks…
Strong and sustained share price appreciation, solid upside potential, an outlook toward further growth, and approval from Wall Street analysts characterize the three “monster growth stocks” highlighted in today’s article – all of which are hovering at or near one-year highs and have the potential to reach new highs. For these three stocks – including a developmental-stage biopharmaceutical company focused…
Although a controversial decision, the FDA has approved Biogen’s Alzheimer’s drug, Aduhelm – and the decision caused Biogen’s stock to surge more than 60% in one day. On the heels of this, and with novel drug approvals on the rise, the contributors to today’s article discuss Biogen’s approval “and how ‘novel’ drugs can give biotech stocks a leg up ……
“There are massive opportunities in the gene-editing space, but there are also a number of risks investors should know before jumping in,” advise the authors of today’s article. For a discussion of the risks associated with this exciting space that investors should keep in mind, CLICK HERE.